Abstract. Skeletal unloading resulting from space flight and prolonged immobilization causes bone loss. Such bone loss ostensibly results from a rapid increase in bone resorption and subsequent sustained reduction in bone formation, but this mechanism remains unclear. Osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/ OPG) is a recently identified potent inhibitor of osteoclast formation. We studied effects of OPG administration on tail-suspended growing rats to explore the therapeutic potential of OPG in the treatment and prevention of bone loss during mechanical unloading, such as that which occurs during space flight. Treatment with OPG in tail suspension increased the total bone mineral content (BMC g) of the tibia and femur and the total bone mineral density (BMD g/cm 2 ) of the tibia. Moreover, treatment with OPG prevented reduction not only of BMC and BMD, but also of bone strength occurring through femoral diaphysis. Treatment with OPG in tailsuspended rats improved BMC, BMD and bone strength to levels of normally loaded rats treated with vehicle. Treatment with OPG in normally loaded rats significantly decreased urinary excretion of deoxypyridinoline, but the effect of OPG in tail suspension was unclear. These results indicate that OPG may be useful in inhibiting bone loss-engendered mechanical unloading.
Skeletal unloading during space flight causes bone mass loss in humans and rats [1] . Calcaneus bone mineral density (BMD) changed in all nine astronauts of the 28-, 59-, and 84-day Skylab missions [2] . Among Skylab missions, bone density loss was greater during the 84-day mission than in shorter missions. Similar bone density changes were observed in Salyut-6 astronauts [2] . Studies using growing rats in space have revealed decreased trabecular bone volume in the tibial proximal metaphysis [3] . Such bone loss resulted mainly from bone formation inhibition [2, 3] .
In terms of both size and scope, costs have limited the studies addressing bone metabolism in space. Therefore, ground-based models have been developed to study consequences of skeletal unloading similar to those that occur during space flight. The most popular model for human studies is bed rest with a head-down tilt. In animals, the tail suspension model is more useful and popular than models involving tenotomy, sciatic neurectomy [4] , casts [5] , and taping of the legs [6] . Tail suspension is not so stressful and it may simulate fluid shift conditions.
Various agents, including parathyroid hormone (PTH), growth hormone (GH), insulin-like growth factor-1 (IGF-1) and bisphosphonates have been used to prevent bone loss induced by skeletal unloading [7] [8] [9] [10] . Intermittent administration of PTH did not significantly reduce the deficit in tibial fat-free weight induced by unloading, but increased periosteal bone formation at the tibiofibular junction and midshaft [7] . GH administration in young hypophysectomized rats increased bone mass, but responses in trabecular bone volume in the proximal tibia and bone formation at the tibiofibular junction to GH were reduced significantly by skeletal unloading [8] . Continuous infusion of IGF-I increased bone mineral density (BMD) at the metaphysical area in unloaded rats [9] . Treatment with a bisphosphonate, pamidronate, increased the total BMD in addition to that of the metaphysis of the femur, but it showed almost no effect on the BMD of the diaphysis in both control and tail-suspended rats [10] .
Osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) is a recently identified potent inhibitor of osteoclast formation and activities. Recombinant human OPG specifically acts on bone tissues and increases BMD and bone volume associated with a decrease of active osteoclast numbers in normal rats. It also blocks bone loss in ovariectomized rats [11] , indicating that OPG is a potent drug for bone loss prevention.
This study was intended to explore the therapeutic potential of OPG in the treatment and prevention of bone loss during skeletal unloading, such as during space flight.
Materials and Methods

Animals
We examined 30 six-week-old male Wistar rats (Japan SLC Inc., Shizuoka, Japan). The animals were individually housed and fed standard laboratory rat chow (Oriental MF; Oriental Yeast Co. Ltd., Tokyo, Japan) containing 1.11% calcium, 0.83% phosphorus, and 108 IU/100 g of vitamin D 3 . They were maintained on a 12 h light, 12 h dark cycle. After one week of acclimation, 24 animals were suspended by their tails and allocated randomly to the OPG-treated group (n = 12, the TS-OPG group) or vehicle-treated group (n = 12, TS-vehicle group). Six animals were normally loaded and randomly allocated to the OPG-treated group (n = 3, NL-OPG group) or vehicle-treated group (n = 3, NL-vehicle group). Data of the normally loaded groups were not diverse, therefore few animals were used in these groups.
A single strip of surgical tape was wrapped around the tail of tail-suspended rats. One end of a chain was fixed to the tape with a wire and the other end was fixed to a horizontal bar, the height of which was adjusted to maintain the rat in a position with about a 40°head-down tilt. Thereby, the hindlimbs were unable to contact any supportive surface [9, 12, 13] .
The animals in the OPG-treated groups were injected intramuscularly with 500 lg/kg of body weight/day of recombinant human OPG (rhOCIF) (Snow Brand Milk Products, Co., Ltd., Tochigi, Japan). The animals in the other groups were injected with vehicle every day for 10 days after which they were sacrificed by exsanguination. Their hindlimb bones and humeri were excised and their length was measured using a vernier caliper. Immediately after excision of femora, tibiae and humeri, all bones were used for analysis of BMD. The femora were also used for bone strength analysis.
Plasma and Urine Biochemistry
Urine samples were obtained before tail suspension and at days 4 and 10. Blood samples were obtained from the inferior vena cava at exsanguinations. Serum calcium and phosphorus concentrations were determined by the orthocresolphthalein complexone (OCPC) method using the Wako kit 272-21801 (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and the p-methylaminophenol reduction method using the Wako kit 270-49801.
Pyridinoline and deoxypyridinoline concentrations in urine were measured as reported previously at the Mitsubishi Laboratory [14] . The pyridinoline/creatinine and deoxypyridinoline/creatinine at pre-treatment were baseline, and the changes in bone marker values from the baseline at days 4 and 10 were expressed as a percentage of the baseline value.
Bone Analysis
Bone Mineral Density. The BMD (g/cm 2 ) and BMC (g) of the right femora, tibiae, and humeri were measured by dual-energy X-ray absorptiometry (DXA) using QDR-1000 (Hologic, Inc., Waltham, MA, USA) at high resolution mode. In addition, the BMD and BMC of the femora were determined in four divided regions with equal longitudinal length (region 1 representing the distal femur, regions 2 and 3 the midshaft femur, and region 4 the proximal femur). Regions 1 and 4 represented the proximal metaphysis and the distal metaphysis (containing a high percentage of trabecular structures). Regions 2 and 3 represented the diaphysis (mainly cortical structure [15] ).
Bone Strength. Mechanical strength of the right femur was measured by the three-point bending method using a Bone Strength Tester TK-252C (Muromachi Kikai Co. Ltd., Tokyo, Japan). Tests were conducted with the femur at the midlength supported on anterior sides. Distance between the bottom supports was 12 mm. Bending force was applied with a crosshead speed of 2.5 mm/min until fracture occurred. The ultimate force (N) was obtained from the load-deformation curve.
Statistical Analysis. Values are expressed as respective means ± standard deviation (SD). Data were analyzed by one-way analysis of variance followed by a post hoc test of Fisher's PLSD test to evaluate intergroup differences among all groups. P < 0.05 was considered to be statistically significant.
Results
Body Weight, Plasma and Urine Biochemistry
All rats remained healthy and their body weights increased gradually. There was no significant difference in the body weights of OPG-treated group rats and vehicletreated group rats in the same condition, but the weight of normally loaded groups (the NL-vehicle group and the NL-OPG group) was increased significantly compared with tail-suspended groups (the TS-vehicle and the TS-OPG group) ( Table 1) . Serum calcium and phosphorus levels were not significantly different among the four groups (Table 2) .
OPG is a bone resorption inhibitor [11] . The urinary excretion of pyridinoline and deoxypyridinoline, both markers of bone resorption, were determined for the purpose of evaluating total body bone resorption activities. Treatment with OPG significantly decreased urinary excretion of deoxypyridinoline in the normally loaded groups (NL-OPG vs NL-vehicle), but the effect of OPG in the tail-suspension groups (TS-OPG vs TSvehicle) was unclear (Table 3) . Bone Length and Bone Mineral Measurements. Tibia and femur length showed no significant differences among the four groups (Table 4) . Humeri in the normally loaded groups (the NL-vehicle group and the NL-OPG group) were significantly longer than in the TS-vehicle group. Regarding the tibiae, the BMC and the BMD in the TS-OPG group were significantly higher than that in the TS-vehicle group; the BMD in the normally loaded groups (the NL-vehicle group and the NL-OPG group) was significantly higher than that in the TS-vehicle group. Femurs of the rats showed that BMD in the TS-OPG group did not increase significantly, but BMC in the TS-OPG group was significantly higher than in the TS-vehicle group. The BMDs in the normally loaded groups (the NL-vehicle group and the NL-OPG group) were significantly higher than those in the tail-suspended groups. For the humeri, BMC and BMD among the four groups were not significantly different. In the regional BMC and BMD of the femur, the BMC of regions 1-3 and the BMD of regions 1-2 in the TS-OPG group were significantly higher than in the TS-vehicle group. The BMDs of regions 1 and 4 in the normally loaded groups (the NL-vehicle group and the NL-OPG group) were significantly higher than in the tail-suspended groups (Table 5 , Fig. 1 ). The BMDs of regions 1 and 4 in the TS-OPG group were significantly lower than in the NL-vehicle group. Notwithstanding, the BMDs of regions 2-3 in the TS-OPG group were nearly equal to those in the NL-vehicle group.
Bone Strength of Femoral Midshaft. Bone strengths of the femoral midshaft in the TS-OPG and the NL-vehicle group were significantly higher than in the TS-vehicle group. Bone strength in the NL-OPG group was significantly higher than in the other groups (Table 6) .
Discussion
This study uses few animals in normally loaded groups (NL-OPG and NL-vehicle). Tables 1-5 show that data of normally loaded groups were not so diverse therefore few animals were used in these groups. Bone formation is reportedly reduced in skeletal unloading models [16] . However, the role of bone resorption in bone loss induced by unloading appears inconsistent because of its transient nature. For example, most tail-suspension models [9, 17, 18] have failed to show increased osteoclast numbers and activity in cancellous tissue at day 7 [17] or day 14 [9, 18] . In contrast, urinary excretion of deoxypyridinoline in tail-suspended rats increased at day 1 and day 3 [19, 20] .
OPG is a bone resorption inhibitor [11] . Bekker et al. [26] reported that OPG treatment in postmenopausal women inhibited bone resorption dose-dependently, as reflected by bone resorption marker profiles (urinary deoxypyridinoline and N-telopeptide). In the present study, urinary excretion of deoxypyridinoline in the NL-OPG group was significantly lower than in the NL-vehicle group at days 4 and 10, implying that OPG treatment reduced bone resorption in the normally loaded groups. Nevertheless, the effect of OPG was unclear in the tail-suspended groups. Deranged bone metabolism during tail-suspension, not only in the unloaded hindlimbs but also in the whole body (forelimbs were overloaded), may explain that insufficient clarity in results. Urinary excretions of pyridinoline and deoxypyridinoline in the TS-OPG group tended to be lower, but not significantly lower than those in the TS-vehicle group at day 4. Such was not the case at day 10. Therefore, we infer that the effect of OPG in the case of tail-suspension might be clearer in early phases.
Matsumoto et al. demonstrated that the decrease in BMD of the femoral diaphysis (rich in cortical bone) was smaller than that in BMD of the metaphysis (rich in trabecular bone) during 7-day tail-suspension. Although 14-day tail-suspension decreased the BMD of the diaphysis markedly, the decrease in the BMD at the metaphysis was not as advanced as with 7-day tail-suspension [21] [22] [23] . Bone strength of the femoral midshaft was not affected until 7 days, but was markedly reduced after 14 days [21] . Therefore, the trabecular bone was reduced during the early phase, but the decrease in the cortical bone was delayed. This delayed decrease in the BMD of the diaphysis in 14-day tail-suspension resulted mainly from impairment of cortical bone formation [21- 23]. Kodama et al. [10, 21] reported that agents reversing the inhibition of periosteal bone formation are required to restore normal bone strength and geometry in situations of prolonged mechanical unloading. These findings suggest that bone-forming agents might be more useful than agents that inhibit bone resorption for prevention of bone loss or decrease in bone strength of the diaphysis induced by long-term unloading over 14 days. For example, high-dose intermittent administration of human PTH, a boneforming agent that prevents change of trabecular bone volume, structure, and bone formation rate induced prolonged mechanical unloading (2-6 wk) in neurectomized mice [27] .
Moreover, Kodama et al. demonstrated that pamidronate, an antiresorptive agent, increased the overall BMD as well as femoral metaphysis. However, it showed almost no effect on the BMD of the diaphysis or bone strength of the femoral midshaft in either control or tail-suspended rats [10] . In the present study, treatment with OPG in tail-suspension increased not only the total BMC of the tibia and femur, but also BMC and BMD of the femoral diaphysis. Moreover, OPG prevented reduction in bone strength measured by three-point bending of the femoral midshaft during tail suspension. Actually, treatment with OPG in tail suspension brought the BMD and bone strength of the midshaft to a level that was nearly equal to that in the NL-vehicle group. These findings differed from those in treatment with bisphosphonates. Inhibitory effects of bisphosphonates on bone mineralization may explain this difference. Francis et al. [24] reported that bisphosphonates inhibited formation of calcium phosphate crystals in vitro [24] . Apseloff et al. [25] reported that aminohydroxybutane bisphosphonate (AHBuBP) could not prevent reduction in bone strength of the femoral diaphysis. They suggested that newly formed bone was weaker in AHBuBP-treated rats. Along with bisphosphonate, OPG is a potent bone resorption inhibitor, but treatment with high doses of OPG alone increased BMD and bone volume and caused neither histopathological abnormalities in other tissues nor significant changes in the number of leukocytes, erythrocytes, reticulocytes, or platelets [11] . Therefore, OPG may act solely on osteoclasts by inhibiting their formation. This inhibition may, at least in part, explain the difference between the two potent bone resorption inhibitors.
In summary, the present findings indicate that treatment with OPG can prevent decrease in BMD not only in cancellous bone but also in cortical bone of the femur. Treatment with OPG can prevent decrease in bone strength at the diaphysis of the femur. These findings suggest that OPG may be useful to treat osteoporosis induced by skeletal unloading, including space flight, and especially to prevent bone fracture during and after space flight. 
